trending Market Intelligence /marketintelligence/en/news-insights/trending/CsitGZKtqqVZD-ZCnezJ8A2 content esgSubNav
In This List

Aviragen Therapeutics to reduce staff, seeking strategic alternatives

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Aviragen Therapeutics to reduce staff, seeking strategic alternatives

Aviragen Therapeutics Inc. is reducing its head count by 25% as it explores strategic alternatives of the business, including a combination or merger.

Stifel Nicolaus & Co. Inc. will advise the company during the review process.

The company said it will not proceed with the planned phase 2 trial of Vapendavir in hematopoietic stem cell transplant patients, though it continues to evaluate a potential clinical development path for the drug.

Meanwhile, top-line efficacy data from the phase 2 trial evaluating BTA074 to treat condyloma caused by human papillomavirus is expected in the first half of 2018.